Saturday 17 October 2026 Export STRO’s income statement to Excel — free account

Sutro Biopharma, Inc.

Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.

10.87 0.59 −5.15%

Follow STRO

Alert me

Market cap: $190.0M
P/E: 0.0×
Fwd P/E: −3.0×
Dividend yield: —
F-score: 3/9
Altman Z: −9.58
Beneish M: −3.10
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.29%

Capital & Financial Ratios $m

Market Cap 190.02

Revenue 45.70

Net Income (180.64)

Free Cash Flow (145.62)

Net Debt (164.35)

Current Ratio 3.32

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.98)

P/S ratio 3.94

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 64.30%

Next Y EPS Growth 20.41%

Next Y revenue growth (49.70%)

Next 5Y EPS Growth 34.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 41.15%

10-year low 10-year high

EV/Sales against its own 10 years 6.91%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	376	317	141	164
Receivables	36	9	4	6
Inventory	—	—	—	—
Other	—	—	—	—
	422	343	151	176

	2023	2024	2025	Q'26
Payables	9	10	8	3
ST’ Debt	4	—	—	—
Other	—	—	—	—
	94	132	75	53

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.12%	14.78%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	10	—	—	—
’25	17	64	10	12	102
’24	13	26	9	15	62
’23	13	10	17	114	154
’22	6	28	25	9	68
’21	15	28	9	11	62
’20	7	9	18	8	43

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(38)	—	—	—
’25	(68)	(45)	(38)	(26)	(177)
’24	(65)	9	(65)	(72)	(192)
’23	(61)	(31)	(34)	14	(112)
’22	(35)	(3)	66	(24)	4
’21	(30)	(5)	(24)	(22)	(82)
’20	(19)	(12)	(18)	(19)	(68)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(42)	(38)	—	—	—
’25	(69)	(45)	(38)	(27)	(179)
’24	(65)	9	(65)	(73)	(195)
’23	(62)	(33)	(34)	13	(116)
’22	(37)	(5)	65	(27)	(4)
’21	(33)	(11)	(29)	(24)	(97)
’20	(19)	(14)	(21)	(21)	(75)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.94)	(2.33)	—	—	—
’25	(9.10)	(1.40)	(6.70)	(5.35)	(22.49)
’24	(9.50)	(5.90)	(5.90)	(8.90)	(29.60)
’23	(8.50)	(6.40)	(8.10)	5.20	(17.80)
’22	(8.40)	(5.50)	(3.70)	(6.10)	(23.50)
’21	(6.60)	(1.30)	(6.70)	(8.30)	(22.90)
’20	(8.40)	9.40	4.50	(14.80)	(9.90)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	85.00	76.90	60.00	140.30	33.30	20.10	17.00	5.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	159.00	124.90	254.90	283.00	156.70	87.20	61.30	21.50
People
People	Employees	—	128	147	168	191	224	278	324	310	137
	Revenue/emp, $m	0.00	0.40	0.26	0.25	0.22	0.28	0.24	0.47	0.20	0.75
Income, $m
Income, $m	Revenue	60	52	38	43	43	62	68	154	62	102
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	2	(20)	(35)	(56)	(32)	(106)	(117)	(89)	(225)	(191)
	EBT margin, %	2.85	(38.05)	(91.93)	(130.44)	(74.96)	(170.55)	(172.20)	(57.63)	(362.81)	(186.55)
	Net income	2	(20)	(35)	(56)	(32)	(106)	(119)	(107)	(227)	(191)
	Depreciation	6	5	4	3	5	8	5	(2)	(3)	4
Per share, $
Per share, $	Revenue	1,464.00	1,154.93	66.71	18.61	13.12	13.42	13.36	25.55	8.02	12.06
	Earnings	41.72	(439.52)	(61.30)	(24.30)	(9.90)	(22.90)	(23.50)	(17.80)	(29.60)	(22.49)
	Cash flow	(322.38)	(827.52)	22.02	(28.32)	(20.82)	(17.71)	0.70	(18.55)	(24.76)	(20.86)
	Capex	(107.30)	(74.02)	(2.70)	(1.52)	(2.19)	(3.32)	(1.55)	(0.72)	(0.40)	(0.20)
	Free cash flow	(429.68)	(901.54)	19.32	(29.84)	(23.00)	(21.03)	(0.85)	(19.27)	(25.16)	(21.06)
	Book value	284.83	(145.00)	228.41	42.59	101.94	54.76	42.78	24.87	5.76	(15.59)
	Shares, m	0	0	1	2	3	5	5	6	8	8
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	1.35	5.91	16.55	11.09	6.00	1.79	2.29	0.96
	P/B	0.00	0.00	0.39	2.58	2.13	2.72	1.87	1.84	3.19	0.00
	EV/Sales	0.00	0.00	(3.59)	3.38	8.53	8.30	1.31	(0.60)	(2.69)	(0.34)
	EV/FCF	0.58	0.58	(12.39)	(2.11)	(4.87)	(5.29)	(20.62)	0.80	0.86	0.20
Cash, $m
Cash, $m	Operating cash flow	(13)	(37)	13	(65)	(68)	(82)	4	(112)	(192)	(177)
	Capex	(4)	(3)	(2)	(3)	(7)	(15)	(8)	(4)	(3)	(2)
	Free cash flow	(18)	(40)	11	(69)	(75)	(97)	(4)	(116)	(195)	(179)
Balance, $m
Balance, $m	Working capital	0	(6)	174	96	349	177	287	328	211	76
	Total debt	1	15	15	10	25	25	16	4	—	—
	Net debt	(46)	(7)	(190)	(108)	(344)	(173)	(318)	(372)	(317)	(141)
	Shareholders’ equity	12	(6)	132	98	332	253	217	150	45	(132)
Returns, %
Returns, %	ROA	3.09	(35.78)	(26.76)	(29.38)	(11.67)	(28.70)	(31.86)	(24.34)	(53.02)	(68.12)
	ROIC	0.00	0.00	0.00	0.00	0.00	(77.22)	0.00	0.00	0.00	0.00
	ROE	(1.70)	19.70	(313.40)	(48.62)	(14.95)	(36.11)	(50.77)	(58.25)	(234.19)	435.02

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGEN Compugen Ltd.	$197.0M	5.2×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
STRO Sutro Biopharma, Inc.	$190.0M	— (loss-making)	— (loss-making)	−84.57% (below 0%: shrinking)	n/m	+14.55% (above 0%: growing)	100.00%	(303.77%)
YARW Yarrow Bioscience, Inc	$188.8M	— (loss-making)	— (loss-making)	+40.58% (above 0%: growing)	n/m	+81.56% (above 0%: growing)	100.00%	(3,197.94%)	Compare
TRDA Entrada Therapeutics, Inc.	$186.1M	— (loss-making)	— (loss-making)	−53.95% (below 0%: shrinking)	n/m	−9.10% (below 0%: shrinking)	100.00%	(5,007.02%)	Compare
UPB Upstream Bio, Inc.	$184.6M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$184.5M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
SION Sionna Therapeutics, Inc.	$184.5M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
ACOG Alpha Cognition Inc.	$184.0M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
Median of peers	$185.4M	—	—	+21.38%	—	−15.75%	94.80%	(235.82%)

All 614 Biotechnology stocks →

Sutro Biopharma, Inc. (STRO) key facts

Strength: Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024.
Sutro Biopharma, Inc. (STRO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, STRO traded at $10.87, a market capitalization of $190.0 million.
Return on equity was 435.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −9.58 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.